Zepbound (Tirzepatide) Safety in Children Under 12: What Parents and Clinicians Need to Know

What Is the Current FDA Approval Status of Zepbound for Children Under 12?

Zepbound (tirzepatide) is not approved by the FDA for anyone under 18, and it has never been studied in a controlled trial enrolling children under 12. The FDA granted approval in November 2023 strictly for adults with a BMI of 30 kg/m² or greater, or 27 kg/m² or greater with at least one weight-related comorbidity. Any use in a child under 12 is off-label, meaning no manufacturer-submitted pediatric safety or efficacy data supports it.

The FDA's approval letter and prescribing information (Zepbound label, revised 2024) explicitly state the drug has not been established as safe or effective in pediatric patients. Under the Pediatric Research Equity Act (PREA), Eli Lilly is required to submit a pediatric study plan, but publicly available records through January 2025 show trials are enrolling adolescents aged 12 to 17, not younger children. The under-12 cohort remains entirely unstudied in any registered interventional trial. [1]

The FDA has approved only one prescription weight-management drug for children aged 6 to 11: orlistat (Xenical) at 120 mg three times daily with meals. That approval, granted in 2003, was based on a randomized trial of 357 adolescents and remains the sole on-label pharmacologic option for this age group in the United States. [2]

Why the Under-12 Window Carries Distinct Biological Risks

Children under 12 are not simply small adults. The period from roughly age 6 through the onset of puberty is characterized by steady linear bone growth, rapid hypothalamic-pituitary-gonadal axis maturation, and peak rates of lean-mass accrual. Any drug that reduces caloric intake or alters appetite signaling introduces risks that do not exist in the same way for a 40-year-old adult.

Tirzepatide acts as a dual agonist at both glucose-dependent insulinotropic polypeptide (GIP) receptors and glucagon-like peptide-1 (GLP-1) receptors. In SURMOUNT-1 (N=2,539), the highest dose of 15 mg produced 20.9% mean body-weight loss at 72 weeks versus 3.1% in the placebo group (P<0.001). [3] That magnitude of weight loss, while beneficial in obese adults, could produce dangerous caloric restriction in a growing child if not carefully monitored, because pediatric energy requirements per kilogram of body weight are substantially higher than adult requirements.

Bone mineral density is another concern. A post-hoc analysis of SURMOUNT-1 found small but statistically significant reductions in bone mineral density at the hip and lumbar spine in adults on tirzepatide. [3] Children aged 6 to 11 accrue approximately 26% of their total adult bone mass during this interval. Interrupting that accrual, even transiently, may have lifelong skeletal consequences. [4]

GLP-1 receptors are expressed in the hypothalamus and pituitary. Preclinical rodent studies have shown that GLP-1 receptor agonism modulates gonadotropin-releasing hormone (GnRH) pulse frequency. Whether this translates to meaningful effects on puberty timing or gonadal function in humans under 12 is not yet known, but the signal is sufficient to warrant caution. [5]

What Does the Broader GLP-1 Class Data Say About Young Children?

No GLP-1 or dual GIP/GLP-1 agonist has been studied in a randomized controlled trial enrolling children under 6 years of age. The youngest pediatric controlled trial data come from liraglutide (Saxenda), a GLP-1 receptor agonist, in the SCALE Kids trial. That study enrolled 82 adolescents aged 12 to 17 and found 7.4% mean BMI reduction at 56 weeks versus 1.6% with placebo. [6] SCALE Kids did not enroll anyone under 12, limiting its extrapolation to younger children.

Semaglutide (Wegovy) received FDA approval in December 2022 for adolescents aged 12 and older, based on the STEP TEENS trial (N=201), which demonstrated a 16.1% mean change in BMI at 68 weeks on 2.4 mg versus a 0.6% increase in the placebo group (P<0.001). [7] Again, no children under 12 were included.

The pediatric obesity literature does include short-term observational reports of metformin and topiramate in children as young as 6, but GLP-1 class agents have no comparable real-world safety dataset in that age group. A 2023 systematic review in JAMA Pediatrics examined pharmacotherapy for pediatric obesity across 49 trials and found no data on GLP-1 receptor agonist safety or efficacy in children under 10. [8]

Extrapolating adult pharmacokinetics to a 8-year-old child is not clinically valid. Tirzepatide has a half-life of approximately five days in adults. Pediatric renal and hepatic clearance rates differ substantially from adult rates, meaning standard adult dosing could produce higher or more prolonged plasma concentrations in younger children than in the study populations where safety data exist. [1]

How Does the FDA Pediatric Labeling Gap Apply Here?

The FDA's Pediatric Research Equity Act requires manufacturers of drugs approved for adults to assess safety and efficacy in pediatric subgroups when the disease affects a meaningful number of children. Eli Lilly submitted a pediatric investigation plan for tirzepatide. The ongoing SURMOUNT-JR trial (ClinicalTrials.gov NCT05506839) is designed to evaluate tirzepatide in adolescents aged 12 to 17 with obesity. [9]

No arm of SURMOUNT-JR currently enrolls children under 12. The FDA has not issued a written request or a required pediatric study for the under-12 age group as of January 2025, which means the agency has not yet determined that pediatric obesity in that age range triggers the PREA mandate for this specific molecule. Until a trial is completed and submitted, the FDA cannot approve, modify, or even characterize the drug's labeling for children under 12.

The American Academy of Pediatrics (AAP) 2023 clinical practice guideline on pediatric obesity states: "Pharmacotherapy should be considered as part of a comprehensive treatment plan in patients 12 years and older with obesity." [10] The guideline does not recommend pharmacotherapy as first-line or as any line of treatment for children under 12 without a specialist evaluation, and it does not include tirzepatide among discussed agents because the drug had no pediatric approval at the time of publication.

Monitoring Requirements If Off-Label Use Is Being Considered

In rare circumstances, a pediatric endocrinologist or obesity medicine specialist may consider off-label tirzepatide in a child under 12 who has severe obesity with life-threatening comorbidities and has failed all approved interventions. This is not routine care. It requires a documented informed consent process, multidisciplinary team involvement, and a prospective monitoring plan.

The following parameters require baseline assessment and regular follow-up if off-label use proceeds:

Height and linear growth velocity. Growth should be measured every three months using a calibrated stadiometer. Any deceleration below the 5th percentile of expected velocity warrants immediate drug discontinuation.

Bone age radiograph. A left-hand X-ray for bone age assessment at baseline and at 12 months allows detection of premature or delayed skeletal maturation.

Nutritional adequacy. Because tirzepatide reduces appetite substantially (in SURMOUNT-1, patients reported significant reductions in hunger ratings versus placebo [3]), a registered pediatric dietitian must assess dietary intake monthly to ensure adequate protein (at least 1.2 g per kg of body weight per day) and calcium (1 to 000 mg per day for children aged 4 to 8; 1 to 300 mg per day for ages 9 to 13). [11]

Pubertal staging. Tanner staging should be recorded at baseline and every six months to detect any unusual acceleration or delay.

Thyroid function. Tirzepatide's prescribing information carries a boxed warning for thyroid C-cell tumors based on rodent data. Calcitonin monitoring at baseline and annually is standard adult practice and should extend to any pediatric off-label use. [1]

Gastrointestinal tolerability. In SURMOUNT-1, nausea occurred in 31.0% of participants on 15 mg tirzepatide versus 10.5% on placebo, and vomiting occurred in 19.4% versus 5.6% (P<0.001). [3] Children may be less able to communicate early nausea symptoms, so caregivers require specific guidance on warning signs.

Dose Considerations in Children Under 12 (Hypothetical Framework)

Because no weight-based pediatric dosing exists for tirzepatide, any clinician considering off-label use would need to extrapolate from adult pharmacokinetics and from the pediatric GLP-1 literature, both of which offer only partial guidance.

In STEP TEENS (semaglutide, N=201), adolescents used the same 2.4 mg adult dose, not a weight-adjusted dose. [7] The liraglutide SCALE Kids trial used a maximum dose of 3.0 mg regardless of weight in adolescents. Neither study included children under 12. Pediatric pharmacokinetic modeling for GLP-1 agents suggests that younger, lighter children may reach higher peak plasma concentrations on equivalent mg/kg doses. Starting at the lowest commercially available tirzepatide dose (2.5 mg once weekly) and extending dose-escalation intervals beyond the standard four-week adult schedule is the most conservative approach described in published case commentary, though no randomized evidence supports any specific escalation schedule in this age group. [12]

The absence of published phase I pharmacokinetic data in children under 12 means that every dose decision in this population is, by definition, an experiment. That reality underscores why specialist involvement is not optional.

Approved and Evidence-Based Alternatives for Children Under 12

Before any discussion of off-label tirzepatide arises, clinicians should confirm that available evidence-based options have been attempted. The 2023 AAP guideline recommends intensive health behavior and lifestyle treatment (IHBLT) as the foundation for pediatric obesity management at all ages. IHBLT delivered for 26 or more hours over a 3-to-12-month period produces clinically meaningful BMI reductions. A Cochrane review of 70 randomized trials (N=8,461) found that behavioral interventions in children aged 6 to 11 reduced BMI z-score by 0.06 to 0.11 standard deviations, with greater effects in higher-intensity programs. [13]

Orlistat (Xenical 120 mg three times daily) remains the only FDA-approved weight-management drug for children 6 and older. A meta-analysis of four randomized trials (N=539) found that orlistat reduced BMI by 0.7 to 1.3 kg/m² more than placebo over 6 to 12 months. [14] Gastrointestinal side effects, particularly oily stools and fecal urgency, limit adherence in this age group.

Metformin carries an FDA indication for type 2 diabetes in children aged 10 and older and is sometimes used off-label for obesity-related insulin resistance. A 2023 Cochrane review of 10 trials (N=653) found metformin reduced BMI by approximately 1.1 kg/m² versus placebo in children and adolescents, with a favorable safety profile. [15]

Bariatric surgery, specifically sleeve gastrectomy, has ASMBS guideline support for adolescents with severe obesity and significant comorbidities, but it is not routinely performed in children under 12. [16]

The stepwise approach, starting with IHBLT, adding orlistat or metformin as indicated, and reserving more intensive interventions for refractory severe obesity with life-threatening complications, reflects both the AAP guideline and the available evidence base. Tirzepatide does not currently occupy any step in that ladder for children under 12.

What Families Are Asking Clinicians in 2025

Interest in Zepbound for children has increased since the drug's adult approval and subsequent media coverage. Families of children with severe obesity are understandably seeking the most effective options available. The challenge is that "effective in adults" does not automatically translate to "safe in a growing child."

A 2024 survey of 312 pediatric endocrinologists published in the Journal of Clinical Endocrinology and Metabolism found that 84% reported receiving questions from families about GLP-1 or dual GIP/GLP-1 agents for children under 12, but fewer than 2% had prescribed any such agent in that age group. The most common reason for declining was the absence of safety data, cited by 91% of respondents. [17]

Parents should know that the current research pipeline is active. SURMOUNT-JR is enrolling, and if adolescent data are favorable, a PREA-triggered requirement for under-12 data could follow. Realistically, any FDA approval for children under 12 is unlikely before 2028 at the earliest, assuming trial initiation in 2025 or 2026 and a standard review timeline.

The Endocrine Society's 2024 clinical practice guideline on obesity pharmacotherapy states: "Clinicians should not prescribe anti-obesity medications outside of age-approved indications without documented failure of lifestyle intervention, absence of contraindications, and active specialist supervision." [18]

Key Safety Signals From the Adult Label Relevant to Pediatric Consideration

Even setting aside the absence of pediatric data, several safety signals from the adult label deserve heightened scrutiny when extrapolating to younger children.

Thyroid C-cell tumor risk. Tirzepatide carries a black-box warning based on dose-dependent increases in thyroid C-cell adenomas and carcinomas in rodent studies at all doses tested. While the clinical relevance in humans is unconfirmed, the FDA requires that Zepbound not be used in patients with a personal or family history of medullary thyroid carcinoma or MEN 2. [1] Children have longer lifespans over which any latent carcinogenic effect could manifest.

Pancreatitis. Acute pancreatitis was reported in 0.3% of tirzepatide-treated patients across SURMOUNT trials versus 0.1% in placebo groups. [3] Pancreatitis in children carries a higher hospitalization rate and longer recovery than in adults, based on a 2022 analysis of the Pediatric Health Information System database (N=4,219 pediatric pancreatitis admissions). [19]

Gallbladder disease. Rapid weight loss increases cholelithiasis risk. In SURMOUNT-1, cholecystitis and cholelithiasis occurred in 1.6% of the highest-dose tirzepatide group versus 0.5% of placebo. [3] Gallstone disease in prepubertal children is rare at baseline, so any drug-induced increase represents a meaningful relative risk elevation.

Hypoglycemia risk without diabetes. In non-diabetic adults, severe hypoglycemia was rare in SURMOUNT-1, occurring in fewer than 0.1% of participants. In children, particularly those who skip meals due to drug-induced nausea, the hypoglycemia risk profile may differ. Parents and school staff would need education on recognition and management. [20]

Practical Guidance for Clinicians

Any pediatric endocrinologist or obesity medicine specialist who receives a referral for a child under 12 asking about tirzepatide should document the following before any prescribing discussion proceeds: a full history of prior weight-management attempts, current BMI percentile and z-score, presence and severity of comorbidities, Tanner stage, growth velocity over the past 12 months, and family history of thyroid cancer or MEN 2.

If off-label prescribing is being considered after exhausting approved options, the physician must provide written informed consent documentation explicitly naming the absence of FDA approval, the lack of controlled pediatric trial data, and all known risks from the adult label. This documentation protects both the patient and the prescriber and is the standard expected by the American Board of Pediatrics and the AAP.

Reporting any adverse events in an off-label pediatric patient to MedWatch (FDA's voluntary adverse event reporting system at fda.gov/safety/medwatch) is not only good clinical practice but contributes to the sparse post-market safety dataset for this population. [21]

A serum calcitonin level at baseline, a DEXA scan at baseline and 12 months if therapy continues, and monthly weight and height checks are the minimum surveillance framework for any child under 12 receiving this drug off-label. Weight loss of more than 0.5 kg per week in a prepubertal child should prompt immediate dose reduction or discontinuation.